Q3 Cash Drops to $143M as Net Loss Widens to $21.7M; STARBORN-1 Enrollment Slips to 1Q 2027
TARA is trading near its 52-week low of $2.11 (0.0% above the low).
Summary
Protara burned through cash in Q3: unrestricted cash and investments fell to $143.1 million from $161.9 million at the end of Q2, and the net loss widened to $21.7 million ($0.35 per share) from $13.3 million a year earlier as R&D jumped to $16.8 million from $9.6 million. Management still says the balance funds operations into 2028. The bigger news is timing: enrollment in the registrational STARBORN-1 trial of TARA-002 in lymphatic malformations now completes early in 1Q 2027, with a rolling BLA submission in 2H 2027 — a slip from prior expectations. On the positive side, the BCG-Unresponsive cohort of ADVANCED-2 remains on track to finish enrollment by year-end 2026, and THRIVE-3 Phase 2b enrollment is complete with interim IV Choline Chloride data due by year-end 2026. Protara also agreed on November 4 to buy TARA-002 manufacturing assets from Novex Innovations for $8.75 million, bringing production in-house ahead of a potential launch. Watch the year-end 2026 ADVANCED-2 enrollment completion and THRIVE-3 interim results.
At the time of this announcement, TARA was trading at $2.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $125.9M. The 52-week trading range was $2.11 to $7.82. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.